Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- 375 Downloads
Bifeprunox is a partial dopamine agonist with a unique receptor-binding profile and potential antipsychotic properties.
The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia.
Materials and methods
In this 6-week, double-blind, placebo-controlled study, 589 patients were randomly assigned to once-daily treatment with bifeprunox 5, 10, or 20 mg, placebo, or risperidone 6 mg. Efficacy was assessed by changes in symptom rating scales [Positive and Negative Syndrome Scale (PANSS) total and subscale scores; PANSS-derived BPRS scores; Clinical Global Impression—Severity (CGI—S) and Clinical Global Impression—Improvement (CGI—I) scores]. Safety and tolerability were assessed by monitoring adverse events, extrapyramidal symptoms (EPS), laboratory values, electrocardiograms, prolactin levels, and weight.
Compared with placebo, bifeprunox 20 mg produced a statistically significantly greater reduction from baseline to last assessment in the primary efficacy variable (PANSS total score; effect size = −0.339), as well as most secondary efficacy measures. No statistically significant differences in efficacy were seen with lower doses of bifeprunox. The most common treatment-emergent adverse events (TEAEs) noted with bifeprunox were gastrointestinal; no clear dose-related trend in the incidence of any TEAE was observed in the bifeprunox groups. Compared to placebo, treatment with bifeprunox led to small but statistically significant decreases in weight and prolactin levels. EPS were comparable between bifeprunox and placebo. The active reference in this study, risperidone 6 mg, showed statistically significant differences from placebo for the primary efficacy parameter (effect size = −0.628) and all secondary efficacy parameters.
These data suggest that 20 mg of bifeprunox may be efficacious in improving symptoms in patients with an acute exacerbation of schizophrenia. Bifeprunox appeared to be safe and well tolerated by patients in this 6-week study.
KeywordsBifeprunox Schizophrenia Partial dopamine agonist Atypical antipsychotic Symptoms Metabolic Extrapyramidal symptoms Weight Prolactin
This work was sponsored by H. Lundbeck A/S, Solvay Pharmaceuticals, Inc., and Wyeth Pharmaceuticals. Editorial support was provided by Centron.
Dr Casey is a consultant to Abbott Laboratories, Bristol-Myers Squibb, Janssen Pharmaceuticals, Pfizer Inc., Solvay Pharmaceuticals, Inc., Dainippon Sumitomo Pharmaceuticals, and Wyeth Pharmaceuticals. He is on the speakers bureau for Abbott Laboratories, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Pfizer Inc. and receives financial support from the Danicas Foundation. Earl Sands and Hwa-Ming Yang are employees of Solvay Pharmaceuticals, Inc. Jens Heisterberg is an employee of H. Lundbeck A/S.
- American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596–601CrossRefGoogle Scholar
- American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). American Psychiatric, Washington, DCGoogle Scholar
- Cosi C, Carilla-Durand E, Assié MB, Ormière AM, Maraval M, Leduc N, Newman-Tancredi A (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135–144PubMedCrossRefGoogle Scholar
- De Vries MH, Udo de Haes J, Grahnén A, Nyman L, Bergström M, Wall A, Langström B (2003) DU 127090: a novel partial dopamine agonist with antipsychotic activity: pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomography. Schizophrenia Res 60(1 suppl 1):S239–S240Google Scholar
- Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D’Agostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53PubMedCrossRefGoogle Scholar
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35(1):51–68PubMedCrossRefGoogle Scholar
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223PubMedCrossRefGoogle Scholar
- Marquis KL, Hertel P, Reinders JH, van der Neut M, Ronken E, Hesselink MB (2005) Bifeprunox: a novel atypical antipsychotic sharing dopamine D2 receptor partial agonism and serotonin 5-HT1A receptor agonism. Schizophr Bull 31:305Google Scholar
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trials and comparison with national estimates from NHANES III. Schiz Research 80:19–32CrossRefGoogle Scholar
- Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341–356PubMedCrossRefGoogle Scholar
- Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRefGoogle Scholar
- Simpson GM (2005) Atypical antipsychotics and the burden of disease. Am J Managed Care 11(suppl 8):S235–S241Google Scholar
- Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ, for the Section of Pharmacopsychiatry, World Psychiatric Association (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schiz Res 100:20–38CrossRefGoogle Scholar